Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances

Reuters01-10

Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances

Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602303943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-10 01:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602303943","market":"nz","top_or_hot":-1,"title":"Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-10 01:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNXP","symbol_name":"Tonix Pharmaceuticals Holding Co","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9ZV19s:1","article_id":"2602303943","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602303943","pubTimestamp":1767981413,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","BK4139":"生物科技","BK4583":"猴痘概念"},"translate_title":"Tonix Pharmaceuticals发布投资者演示文稿，重点介绍FDA批准和管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNXP":0.9},"content_text":"Tonix Pharmaceuticals Unveils Investor Presentation Highlighting FDA Approvals and Pipeline Advances\n    \n\n        Tonix Pharmaceuticals Holding Corp. has released an investor presentation outlining its current business and clinical development activities. As of September 30, 2025, the company reported approximately $190 million in cash and no debt, with an expected cash runway extending into the first quarter of 2027. Tonix currently has three FDA-approved products and focuses on therapeutic areas including central nervous system disorders and immunology. The presentation highlights the commercial launch of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, with wholesale acquisition costs set at $1,860 for a 60-count and $930 for a 30-count package. The company has deployed 90 sales representatives and established patient access programs. Key pipeline programs include TNX-1500 for prevention of organ transplant rejection, TNX-2900 for Prader-Willi Syndrome, and TNX-4800 for the seasonal prevention of Lyme disease, all in various stages of clinical development. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602303943","isCrawlerRequest":true}